China Manufacturer for Captopril - Venetoclax 1257044-40-8 – CPF
China Manufacturer for Captopril - Venetoclax 1257044-40-8 – CPF Detail:
维奈妥拉 | Venetoclax | 1257044-40-8 | In-House |
VCL-6A | 98549-88-3 | In-House | |
VCL-7A | 1235865-75-4 | In-House | |
VCLM2 | 1228780-72-0 | In-House | |
VCLM2-2HCl | 1628047-87-9 | In-House | |
VCLM3 | 1228779-96-1 | In-House |
Generic Name: venetoclax (ven ET oh klax)
Brand Name: Venclexta, Venclexta Starting Pack
Venetoclax is used to treat chronic lymphocytic leukemia or small lymphocytic leukemia in adults. Venetoclax is used alone or in combination with other cancer medicines to treat these conditions.
Venetoclax is used in combination with azacitidine, decitabine, or cytarabine to treat acute myeloid leukemia. This combination is for use in adults who are 75 years or older, or who cannot use standard chemotherapy due to other medical conditions.
Venetoclax is sometimes given after other treatments have failed.
Venetoclax may also be used for purposes not listed in this medication guide.
Description
Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy.
In Vitro
Venetoclax (ABT-199) potently kills FL5.12-BCL-2 cells (EC50=4 nM), Venetoclax (ABT-199) shows much weaker activity against FL5.12-BCL-XL cells (EC50=261 nM). ABT-199 also shows selectivity in cellular mammalian two-hybrid assays, where it disrupts BCL-2-BIM complexes (EC50=3 nM) but is much less effective against BCL-XL-BCL-XS (EC50=2.2 μM) or MCL-1-NOXA complexes.
After a single oral dose of 12.5 mg per kg body weight in xenografts derived from RS4;11 cells (ALL), Venetoclax (ABT-199) causes a maximal tumor growth inhibition (TGImax) of 47% (P<0.001) and tumor growth delay (TGD) of 26% (P<0.05)[1].
Treatment of established xenografted (a mouse xenograft model of the T-ALL cell line LOUCY) tumors with Venetoclax (ABT-199) 100 mg/kg for 4 days results in a significant reduction of leukemic burden.
Storage
Powder |
-20°C |
3 years |
4°C |
2 years | |
In solvent |
-80°C |
6 months |
-20°C |
1 month |
Chemical structure
Proposal 18 Quality Consistency Evaluation projects which have approved 4, and 6 projects are under approving.
Advanced international quality management system has laid solid foundation for sales.
Quality supervision runs through the whole life cycle of the product to ensure the quality and therapeutic effect.
Professional Regulatory Affairs team supports the quality demands during the application and registration.
VIEW MORE
VIEW MORE
International cooperation
Domestic cooperation
Product detail pictures:
Related Product Guide:
Our products are greatly recognized and trustworthy by users and will fulfill continually shifting economic and social requires for China Manufacturer for Captopril - Venetoclax 1257044-40-8 – CPF , The product will supply to all over the world, such as: Canberra, Salt Lake City, Bahamas, At Present, our products have been exported to more than sixty countries and different regions, such as Southeast Asia, America, Africa, Eastern Europe, Russia, Canada etc. We sincerely hope to establish wide contact with all potential customers both in China and the rest part of the world.
By Victor from Barbados - 2018.09.29 13:24
High production efficiency and good product quality, fast delivery and completed after-sale protection, a right choice, a best choice.
By Modesty from Australia - 2017.08.18 11:04